Answers are grounded in this paper and cite their sources.
In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
No takes yet. Share an insight, caveat, or question.
Francque et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: